Caval Valve Implantation for Tricuspid Regurgitation: Insights From the United States Caval Valve Registry
O'Neill BP, Negrotto S, Yu D, Lakhter V, Depta J, McCabe JM, Dube S, Vaikom M, Wang DD, Patil P, Lindman B, Iglessis-Azuaje I, Fredi J, Lu X, and O'Neill WW. Caval Valve Implantation for Tricuspid Regurgitation: Insights From the United States Caval Valve Registry. J Invasive Cardiol 2020.
The Journal of invasive cardiology
BACKGROUND: We sought to describe the outcomes of patients who underwent caval valve implantation (CAVI) for treatment of severe tricuspid regurgitation (TR) in the United States. Previous studies on CAVI have used a variety of techniques and transcatheter valves. We present our findings from CAVI with inferior vena cava (IVC) implant only using a single valve.
METHODS: Patients who were determined to be poor candidates for tricuspid valve surgery and underwent CAVI in the United States from March 1, 2013 through March 1, 2018 were included in this study. Data during hospitalizations and interim outpatient follow-up from each individual site were collected and entered into a central password-protected database.
RESULTS: A total of 24 patients were treated. The median age was 79.5 years, 63% were women, and 96% were white. Twenty-three of 24 patients underwent valve implantation with a 29 mm Sapien 3 valve (Edwards Lifesciences). There was a 100% rate of successful valve implantation. There were no cases requiring emergency surgery. Thirty-day mortality rate was 25%. The median survival as of last follow-up of all patients was 350 days. Pre- and postprocedure New York Heart Association (NYHA) class data were available in 11 of 24 patients; of these 11 patients, 72.7% improved at least 1 NYHA class from baseline.
CONCLUSION: CAVI may be performed safely in a high surgical risk population with severe tricuspid regurgitation. Dedicated studies with longer-term follow-up are needed.
ePub ahead of print